News
Public · Published
Morgan Stanley maintains Cencora at Overweight, raises price target to $377 from $346
Morgan Stanley kept its Overweight rating on Cencora and raised its price target to $377 from $346, a 9.0% increase. The new target implies 14.1% upside from the October 29 close of $330.53.
Published:
Updated:
What happened
Morgan Stanley kept its Overweight rating on Cencora and raised its price target to $377 from $346, a 9.0% increase. The new target implies 14.1% upside from the October 29 close of $330.53.
Confirmed
Global impact / market context
A higher price target signals the analyst expects more upside in the stock, which can draw investor attention and buying interest. Cencora investors may treat the maintained Overweight rating as a sign that profit expectations for the drug distributor remain intact.
Analyst inference
Other recent analyst targets for Cencora range from $375 to $400, all above the current share price. That clustering suggests broad analyst confidence in the company, though targets are opinions, not guarantees, and do not tell investors what to do personally.
Analyst inference
What to watch
- Watch whether Cencora's share price moves toward Morgan Stanley's $377 target or stays near the $330.53 close, which would show how investors are weighing the raised target. Confirmed
- Track future analyst notes for rating or price target changes, since the article says prior and future recommendations can be followed, giving clues about shifting views on Cencora. Proposed
- Watch Cencora's upcoming results for signs that revenue and costs support higher profit expectations, because analyst targets rest on earnings forecasts that company results can confirm or undercut. Analyst inference
Evidence
- Original source link unavailable